MedTrace Logo

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

NCT01499511 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1718

Last updated 2019-12-03

Study results available
· View outcomes & findings →

Summary

ASCOT-10 is a follow-up study of surviving participants in the United Kingdom (UK)arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) which was conducted between 2000 and 2005.ASCOT's results showed substantial cardiovascular benefit from: 1) the use of a cholesterol lowering drug (atorvastatin) compared to placebo, and 2) the use of a blood-pressure lowering strategy based on amlodipine when compared to a strategy based on atenolol. ASCOT-10 will test the hypothesis that the ASCOT subjects who originally received Atorvastatin and those who received amlodipine based treatment will continue to show a cardiovascular benefit relative to those who did not, even though all the subjects have had access to optimal treatment in the interim.

Conditions

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Judith A Mackay, MBBS PhD MRCP · Imperial College Healthcare NHS Trust

  • Peter S Sever, MBChB FRCP PhD · Imperial College London

  • Simon M Thom, MBBS MD FRCP · Imperial College London

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-05-30
Completion
2016-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499511 on ClinicalTrials.gov